A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Upadacitinib (Primary) ; Tofacitinib
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 26 Oct 2017 Results (n=573) assessing population pharmacokinetics of Upadacitinib in healthy subjects and subjects with rheumatoid arthritis from NCT01741493, NCT02066389, and NCT01960855 studies, published in the Clinical Pharmacokinetics
- 06 Jun 2016 Results published in the Clinical Pharmacokinetics
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.